Breast Care
Review Article · Übersichtsarbeit
Carcinoma of Unknown Primary – an Orphan Disease?Krämer A.a · Hübner G.b · Schneeweiss A.c · Folprecht G.d · Neben K.ea Klinische Kooperationseinheit für Molekulare Hämatologie und Onkologie des Deutsches Krebsforschungszentrums und der Medizinischen Klinik und Poliklinik V der Universität Heidelberg, bSana Kliniken Ostholstein, Oldenburg, c Frauenklinik, Universität Heidelberg, dMedizinische Klinik I, Universität Dresden, e Medizinische Klinik und Poliklinik V, Universität Heidelberg, Germany
Prof. Dr. med. Alwin Krämer, Klinische Kooperationseinheit für Molekulare Hämatologie und Onkologie des DKFZ und der Medizinischen Klinik und Poliklinik V der Universität Heidelberg Im Neuenheimer Feld 581, 69120 Heidelberg, Germany Tel. +49 6221 42144-0, Fax -4 E-mail Alwin_Kraemer@med.uni-heidelberg.de |
|
Abstract
Carcinoma of unknown primary (CUP) is an intriguing clinical finding that is defined as biopsy-proven metastasis from a malignancy in the absence of an identifiable primary site after a complete clinical work-up. CUP is a relatively common clinical entity, accounting for approximately 3–5% of all cancer diagnoses, and consists of a heterogeneous group of tumors that have acquired the capacity to metastasize before the development of a clinically evident primary lesion. Notable advances have been made over the past years in the treatment of well-defined clinical subgroups of CUP, such as women with peritoneal carcinomatosis and young adults with poorly differentiated carcinomas of midline distribution, but for the majority of patients, the prognosis still remains poor. In this review, we highlight recent advances in the diagnosis and treatment of patients with CUP syndrome, and emphasize the importance of identifying several favorable subsets of CUP, amenable to specific treatment options. In addition, we will point out novel diagnostic and therapeutic approaches which will hopefully improve both our understanding and the prognosis of this more or less neglected disease.
© 2008 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Published online: June 19, 2008
Issue release date: July 2008
Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 1
ISSN: 1661-3791 (Print)
eISSN: 1661-3805 (Online)
For additional information: https://www.karger.com/BRC
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
